VRXA (Veraxa Biotech Holding AG) Goodwill-to-Asset: 0.28 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRXA Veraxa Biotech Holding AG VRXA
6 GF Score
Price $1.50
! 3 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Goodwill-to-Asset?

Veraxa Biotech Holding AG VRXA -1.32% 6 Goodwill-to-Asset is 0.28 as of Dec. 2025. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Veraxa Biotech Holding AG's Goodwill for the quarter that ended in Dec. 2025 was $0.00 Mil. Veraxa Biotech Holding AG's Total Assets for the quarter that ended in Dec. 2025 was $270.06 Mil.


Veraxa Biotech Holding AG  (NAS:VRXA) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Veraxa Biotech Holding AG Goodwill-to-Asset Related Terms


Veraxa Biotech Holding AG Goodwill-to-Asset Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Goodwill-to-Asset Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Goodwill-to-Asset
0.25 0.27 0.28

Veraxa Biotech Holding AG Quarterly Data
Jun24 Dec24 Jun25 Dec25
Goodwill-to-Asset 0.00 0.27 0.28 0.28

VRXA vs KRRO, CNXU, NKTX: Goodwill-to-Asset Comparison

For the Biotechnology subindustry, Veraxa Biotech Holding AG's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veraxa Biotech Holding AG Goodwill-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Veraxa Biotech Holding AG's Goodwill-to-Asset falls into.


VRXA
6GF Score
Veraxa Biotech Holding AG VRXA
Goodwill-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Veraxa Biotech Holding AG's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Goodwill to Asset (A: Dec. 2025 )=Goodwill/Total Assets
=0/270.056383
=

Veraxa Biotech Holding AG's Goodwill to Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

Goodwill to Asset (Q: Dec. 2025 )=Goodwill/Total Assets
=0/270.056383
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Goodwill-to-Asset →
What does a Goodwill-to-Asset of 0.28 mean?
Veraxa Biotech Holding AG (VRXA) has a Goodwill-to-Asset of 0.28 as of Dec. 2025. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Veraxa Biotech Holding AG and its competitors.
Is Veraxa Biotech Holding AG's Goodwill-to-Asset too high?
Veraxa Biotech Holding AG's current Goodwill-to-Asset is 0.28. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Goodwill-to-Asset compare to KRRO and CNXU?
Veraxa Biotech Holding AG's Goodwill-to-Asset of 0.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill-to-Asset for a Biotechnology company?
A good Goodwill-to-Asset depends on the Biotechnology industry context. However, Goodwill-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill-to-Asset mean?
A high Goodwill-to-Asset can signal that a stock is expensive relative to its fundamentals. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current Goodwill-to-Asset is 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current Goodwill-to-Asset of 0.28. The current Goodwill-to-Asset is 0.28. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill-to-Asset calculated?
Goodwill-to-Asset is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current Goodwill-to-Asset is 0.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges J8L0:Germany
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score

Get the complete analysis for VRXA

Goodwill-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.50
Price